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Abstract
Background: Several studies have investigated the effect of intraoperative blood loss (IBL) on recurrence of tumors.
However, the independent effect of IBL on oncological outcome after liver transplantation (LT) for hepatocellular
carcinoma (HCC) is unclear.
Methods: A total of 479 patients who underwent LT for HCC from January 2001 to December 2012 at our institution
were enrolled in this retrospective study. Kaplan–Meier and Cox regression methods were used to assess the recurrence
rate, as well as its risk factors. Stratified analysis was performed to further examine the effect of IBL on HCC recurrence
according to different characteristics of tumors. We also investigated the independent risk factors for excessive IBL using
logistic regression analysis.
Results: The median follow-up was 28 months (range, 1–131 months). Kaplan–Meier analysis with the log-rank test
according to IBL at per liter intervals showed that IBL > 4 L was significantly associated with a higher recurrence
rate (P < 0.001). Multivariate analysis identified that IBL > 4 L (P < 0.001; hazard ratio [HR] = 2.32, 95 % confidence
interval [CI] = 1.60–3.36) was an independent risk factor for post-LT HCC recurrence, as well as age < 60 years,
exceeding Milan criteria, α-fetoprotein levels > 400 ng/mL, and micro- and macrovascular invasion. IBL > 4 L (P < 0.001;
HR = 2.45, 95 % CI = 1.64–3.66) was also independently associated with early (within 1 year) recurrence after LT.
Furthermore, a significant correlation between IBL > 4 L and vascular invasion (P = 0.019) was found. IBL > 4 L was
independently associated with HCC recurrence for patients with vascular invasion, but not for patients without
vascular invasion. Finally, we found that the presence of ascites, model for end-stage liver disease score, and
operation time were independent risk factors for IBL > 4 L.
Conclusions: Excessive IBL is an independent predictor of HCC recurrence after LT, especially in patients with
vascular invasion.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related death and is currently the
major event leading to death in patients with cirrhosis
[1]. Liver transplantation (LT) is an ideal treatment for
HCC because it can simultaneously cure the tumor and
underlying cirrhosis. Additionally, the effectiveness of LT
is not affected by the degree of impairment of liver func-
tion [2]. However, this major surgery is often accompan-
ied by excessive intraoperative blood loss (IBL). IBL is a
significant prognostic determinant for hepatocellular
carcinoma [3]. as well as many other cancer types, such
as gastric cancer [4], colorectal cancer [5], prostate cancer
[6], and pancreas cancer [7]. Previous studies have evalu-
ated the relationship of IBL in liver resection with out-
comes in HCC patients. These studies demonstrated that
IBL can independently predict survival and recurrence [3].
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However, there is little research on the effect of IBL on
prognosis after LT for HCC, especially the effect on HCC
recurrence. Furthermore, to the best of our knowledge, no
studies have further investigated the relationship between
IBL and post-transplant HCC recurrence according to dif-
ferent tumor characteristics, such as vascular invasion
status. Therefore, this study aimed to assess the relation-




Medical records of 570 patients who underwent deceased
donor LT at our transplant center between January 2001
and December 2012 were reviewed retrospectively. Of
these patients, 91 were excluded for various reasons as fol-
lows. Forty (7.0 %) patients were pathologically confirmed
as having cholangiocellular carcinoma or mixed liver can-
cer, 24 (4.2 %) died within 1 month after LT without evi-
dence of HCC recurrence, and 27 (4.7 %) had insufficient
data. Finally, 479 patients were enrolled in our study. This
study was approved by the Research Ethics Committee of
Changzheng Hospital, Shanghai and written informed
consents were obtained from all the participants. Demo-
graphic, clinical, and laboratory data were collected from
the records of our center in the China Liver Transplant
Registry database.
Surgery and postoperative management
All patients underwent deceased donor LT using standard
techniques without the use of veno-venous by-pass, and
the piggyback technique was used when necessary. The
post-LT immune suppression regimen included steroids
and tacrolimus or cyclosporine with or without mycophe-
nolate. Steroids were usually discontinued within the first
month after operation. Postoperative adjuvant chemother-
apy was administered according to tumor stage, physical
condition, and the patient’s willingness. An anesthesiologist
and circuit nurse added the blood in laparotomy sponges
to suction containers and IBL was calculated immediately
after surgery. A transfusion event was considered as
administration of allogeneic packed red blood cells.
Follow-up
The follow-up started on the day of LT and was routinely
performed at outpatient clinics. Patients were followed up
every 2 months for the first year after LT, and then at least
every 3–4 months thereafter until death or the end of the
study (December 31, 2014). Serum α-fetoprotein (AFP)
levels, abdominal ultrasonography, and chest X-ray were
monitored at each visit. When tumor recurrence was sus-
pected, computed tomography and/or magnetic resonance
imaging were performed to verify whether intrahepatic re-
currence and/or distal metastasis had occurred. A diagnosis
of recurrence was based on typical imaging appearance on
computed tomography and/or magnetic resonance imaging
scans, with or without raised AFP levels.
Statistical analysis
Categorical variables are reported as frequencies (%) and
were analyzed by the chi-square test. Continuous vari-
ables are shown as mean ± SD and were analyzed using
the Student’s t-test. Patients without evidence of HCC
recurrence at the last follow-up visit were right-censored.
The recurrence-free survival rate and recurrence rate were
estimated using the Kaplan–Meier method, and differ-
ences in the cumulative recurrence curves were compared
by the log-rank test. The Cox proportional hazards re-
gression model was used to identify independent prog-
nostic factors for recurrence. In the analysis for early
(within 1 year) HCC recurrence, follow-up time of the
first postoperative year was used and patients who
developed HCC recurrence after the first year were
right-censored. Interaction between IBL and tumor
characteristics was investigated using the Cox propor-
tional hazard regression model. Independent risk fac-
tors for IBL > 4 L were determined by multivariate
logistic regression analysis. All of the data were ana-
lyzed using the software package SPSS (version 22.0;
SPSS Inc., Chicago, IL, USA) and the level of signifi-
cance was set at P < 0.05.
Results
Patients’ characteristics
The patients’ characteristics are shown in Table 1. The
mean age of the 479 patients was 55.7 years (range: 25–
84 years) and there was a male predominance (n = 435,
90.8 %). The most common cause for LT was hepatitis B
(n = 446, 93.1 %). Pre-transplant tumor therapy for HCC
was performed in 176 (36.7 %) patients. Of these pa-
tients, 54 (11.3 %) had liver resection, 116 (24.2 %) had
transhepatic arterial chemotherapy and embolization, 23
(4.8 %) had radiofrequency ablation, and 12 (2.5 %) had
percutaneous ethanol injection before transplantation.
Liver resection and transhepatic arterial chemotherapy
and embolization were the main downstaging procedures
for patients exceeding the Milan criteria. Among 126
patients receiving downstaging procedures, 41 (32.5 %)
met the Milan criteria after treatments. Fourteen (2.9 %)
patients underwent LT using the piggyback technique.
The mean IBL was 1436 ± 1833 mL, and 359 (74.9 %)
patients received perioperative allogeneic red blood cell
transfusion. Of the 479 patients, 292 patients (61.0 %)
were beyond the Milan criteria.
The median follow-up time for all of the patients who
were enrolled in this study was 28 months (range, 1–
131 months). The 1-, 3-, and 5-year recurrence rates
were 33.3, 44.4, and 46.2 %, respectively (Fig. 1). During
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the follow-up period, 207 (43.2 %) patients experienced
recurrence. Most HCC recurrences (n = 189, 91.3 %)
occurred within 2 years, and 154 (74.4 %) patients ex-
perienced HCC recurrence within 1 year. The median
time to recurrence was 7 months (range, 1–83 months).
Relation between IBL and HCC recurrence after LT
Patients were categorized according to IBL at per liter in-
tervals. Kaplan–Meier analysis with the log-rank test was
used. One- and 3-year recurrence rates were 30.9 and
44.7 % for IBL < 1 L, 28.1 and 37.3 % for IBL of 1–2 L,
37.5 and 48.4 % for IBL of 2–3 L, 33.1 and 43.0 % for IBL
of 3–4 L, and 52.6 and 62.8 % for IBL > 4 L. IBL > 4 L was
significantly associated with a poorer recurrence-free sur-
vival (P < 0.001 for IBL > 4 L vs. ≤ 4 L, Fig. 2). Based on
these results, the threshold for IBL was set at 4 L. Of the
479 patents, 69 (14.4 %) had an IBL > 4 L. The model for
end-stage liver disease (MELD) score (P < 0.001), the pres-
ence of ascites (P < 0.001), blood transfusion (P < 0.001),
and operation time (P = 0.029) were significantly different
between patients with IBL > 4 L and those with IBL ≤ 4 L
(Table 2). Patients’ characteristics, such as age, sex, and
preoperative tumor therapy, tumor factors, such as the
number of tumors, maximum tumor size, vascular inva-
sion, and tumor differentiation, and serum AFP levels
were not significantly different between the two groups. In
univariate analysis, a total of nine factors, including IBL,
had a significant effect on HCC recurrence (Table 3). In
multivariate analysis, IBL > 4 L (P < 0.001; hazard ratio
[HR] = 2.32; 95 % confidence interval [CI] = 1.60–3.36)
was still a significant prognostic factor of recurrence for
HC, as well as age < 60 years (P = 0.033; HR = 1.43; 95 %
CI = 1.03–1.99), exceeding the Milan criteria (P < 0.001;
HR = 2.54; 95 % CI = 1.79–3.59), AFP levels > 400 ng/mL
(P < 0.001; HR = 1.65; 95 % CI = 1.24–2.19), and micro-
vascular (P < 0.001; HR = 1.84; 95 % CI = 1.38–2.47) and
Fig. 1 Kaplan–Meier curves for cumulative recurrence rates after liver
transplantation for the entire patient cohort. The 1-, 3-, and 5-year
recurrence-free survival rates were 33.3 %, 44.4 %, and 46.2%, respectively
Fig. 2 Kaplan–Meier curves for cumulative recurrence rates according
to IBL. One- and 3-year recurrence rates were 30.5 % and 42.0 % for
IBL≤ 4 L, and 52.6 and 62.8 % for IBL > 4 L, respectively
Table 1 Clinicopathological variables
Variable Value
Age (years) 55.7 ± 8.8
Male sex 435 (90.8)
Hepatitis B virus infection 446 (93.1)
Preoperative tumor therapy 176 (36.7)
Child–Pugh score 7.7 ± 2.3
MELD score 12.8 ± 5.8
Piggyback LT 14 (2.9)
Number of tumors > 3 135 (28.2)
Maximum tumor size (cm) 4.8 ± 4.1
AFP levels > 400 ng/mL 176 (36.7)
Poor differentiation 60 (12.5)
Macrovascular invasion 69 (14.4)
Microvascular invasion 134 (28.0)
Beyond Milan criteria 292 (61.0)
Operation time (h) 8.0 ± 1.6
Blood transfusion(yes vs no) 359 (74.9)
Blood transfusion (mL) 1436.8 ± 1833.8
IBL (mL) 2172.5 ± 1854.0
Values are mean ± SD or n (%)
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macrovascular (P < 0.001; HR = 3.19; 95 % CI = 2.30–4.12)
invasion (Table 3).
Relation between IBL and early recurrence of HCC
Approximately three-quarters of recurrence (n = 154,
74.4 %) occurred within 1 year. Therefore, we also evalu-
ated risk factors contributing to early (within 1 year)
recurrence. Cox regression analysis was performed con-
sidering patients without tumor recurrence within 1 year
as right-censored. In multivariate analysis, IBL > 4 L was
an independent predictor of early recurrence (P < 0.001;
HR = 2.45; 95 % CI = 1.64–3.66), as well as the Milan cri-
teria (P < 0.001; HR = 2.12; 95 % CI = 1.41–3.20), AFP
levels > 400 ng/mL (P = 0.001; HR = 1.71; 95 % CI = 1.24–
2.78), and microvascular (P < 0.001; HR = 1.94; 95 % CI =
1.40–2.71) and macrovascular (P < 0.001; HR = 3.26; 95 %
CI = 2.29–4.64) invasion (Table 4).
Table 2 Clinicopathological characteristics according to IBL
Variable IBL≤ 4 L IBL > 4 L P value
(n = 410) (n = 69)
Mean age (years) 55.8 ± 9.1 56.5 ± 8.1 0.545
Male sex 372 (90.7) 63 (91.3) 0.879
Hepatitis B virus infection 383 (93.4) 63 (91.3) 0.522
Piggyback LT 12(2.9) 2(2.9) 0.990
Child-Pugh score 7.36 ± 2.13 9.21 ± 2.38 0.245
MELD score 12.3 ± 5.6 17.8 ± 8.8 <0.001
Ascites 205 (50.0) 55 (79.7) <0.001
Variceal bleeding 49 (12.0) 15 (21.7) 0.027
Preoperative tumor therapy 146 (35.6) 29 (42.0) 0.498
History of abdominal surgery 85 (20.7) 20 (29.0) 0.125
AFP levels > 400 ng/mL 151 (36.8) 25 (36.2) 0.924
Size of largest tumor > 5 cm 122 (29.8) 17 (24.6) 0.386
Number of tumors > 3 117 (28.5) 18 (26.1) 0.676
Macrovascular invasion 55 (13.4) 14 (20.3) 0.103
Microvascular invasion 113 (27.6) 21 (30.4) 0.623
Poor differentiation 50 (12.2) 10 (14.5) 0.594
Beyond Milan criteria 248 (60.4) 44 (63.7) 0.567
Blood transfusion (mL) 1043.6 ± 1467.9 3892.2 ± 1880.8 <0.001
Operation time (h) 7.8 ± 1.5 8.9 ± 1.9 0.029
Values are mean ± SD or n (%)
Table 3 Predictors of recurrence after LT for HCC
Variable Univariate analysis Multivariate analysis
P HR (95 % CI) P
Age <60 years 0.004 1.43 (1.03–1.99) 0.033
Male sex 0.025 1.07 (0.62–1.86) 0.808
Hepatitis B virus infection 0.604
Pre-LT tumor therapy 0.126
MELD score > 15 0.472
AFP levels > 400 ng/mL <0.001 1.65 (1.24–2.19) 0.001
Poor differentiation 0.030 1.26 (0.84–1.88) 0.263
Macrovascular invasion <0.001 3.19 (2.30–4.12) <0.001
Microvascular invasion <0.001 1.84 (1.38–2.47) <0.001
Beyond Milan criteria <0.001 2.54 (1.79–3.59) <0.001
Blood transfusion 0.496
IBL > 4 L <0.001 2.32 (1.60–3.36) <0.001
Operation time > 8 h 0.128
Table 4 Predictors of early recurrence after LT for HCC
Variable Univariate analysis Multivariate analysis
P HR (95 % CI) P
Age <60 years 0.022 1.27 (0.87–1.86) 0.217
Male sex 0.080
Hepatitis B virus infection 0.712
Pre-LT tumor therapy 0.203
AFP levels > 400 ng/mL <0.001 1.71 (1.24–2.78) 0.001
Poor differentiation 0.020 1.31 (0.84–2.03) 0.232
Macrovascular invasion <0.001 3.26 (2.29–4.64) <0.001
Microvascular invasion <0.001 1.94 (1.40–2.71) <0.001
Beyond Milan criteria <0.001 2.12 (1.41–3.20) <0.001
Blood transfusion 0.077
IBL > 4 L <0.001 2.45 (1.64–3.66) <0.001
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Stratified analysis of IBL according to tumor characteristics
For patients within the Milan criteria, the 1-, 3-, and 5-
year recurrence rates were 13.5, 24.2 %, and 27.8 %,
respectively. For patients beyond the Milan criteria, the
1-, 3-, and 5-year recurrence rates were 53.5, 56.0, and
66.7 %, respectively. To further examine the relationship
between IBL and recurrence-free survival, we performed
stratified analysis according to the Milan criteria, status of
vascular invasion, AFP levels, and tumor differentiation.
When patients were categorized according to the vascular
invasion status, IBL > 4 L (P = 0.243) was no longer associ-
ated with a high recurrence rate in patients without vascu-
lar invasion. However, for patients with vascular invasion,
IBL > 4 L (P < 0.001) was still significantly associated with
a higher recurrence rate (Fig. 3). Furthermore, stratified
analysis suggested a significant interaction between IBL >
4 L and vascular invasion (P = 0.019, Table 5). In multivari-
ate analysis for patients with vascular invasion, IBL > 4 L
(P < 0.001; HR = 2.86, 95 % CI = 1.76–4.64) was an
independent predictor of recurrence. However, for patients
without vascular invasion, IBL > 4 L (P = 0.138; HR = 1.57,
95 % CI = 0.87–2.85) was not associated with HCC recur-
rence (Table 6).
Risk factors for excessive IBL
Our results showed that excessive IBL, particularly IBL >
4 L, was a significant predictor for a higher recurrence
rate and early recurrence. Therefore, we evaluated the
potential risk factors related to IBL > 4 L. Clinicopatho-
logical characteristics of patients with IBL ≤ 4 L were
compared with those with IBL > 4 L previously in our
study (Table 2). There were significant differences in the
history of variceal bleeding, the presence of ascites, and
the MELD score between the two groups. In multivariate
analysis using logistic regression analysis, the presence
of ascites (P = 0.006; HR = 2.61; 95 % CI = 1.32–5.14) and
a MELD score > 15 (P < 0.001; HR = 3.25; 95 % CI =
1.84–5.75) were independent risk factors for IBL > 4 L
(Table 7).
Discussion
Characteristics of tumors have been shown to be of
prognostic importance for HCC patients after LT [8–11].
However, other factors may also affect HCC recurrence.
In this study, we assessed the relationship between IBL
and HCC recurrence after LT through comprehensive
evaluation. We found that excessive blood loss, particu-
larly IBL > 4 L, was an independent predictor of HCC
recurrence, especially in patients with vascular invasion.
Previous studies have evaluated the relationship of IBL
with outcome in HCC patients after hepatectomy. Katzet
et al. [3] reported that an IBL volume greater than 1 L dur-
ing liver resection was significantly associated with poor
overall survival, disease-specific survival, and recurrence-
Fig. 3 Kaplan–Meier curves for cumulative recurrence rates classified according to IBL and vascular invasion status. IBL > 4 L was not significantly
associated with HCC recurrence in patients without vascular invasion (a). However, in patients with vascular invasion, IBL > 4 L predicted a significantly
higher recurrence rate (b)
Table 5 Stratified analysis for IBL > 4 L according to tumor
characteristics
HR 95 % CI P value for interaction
AFP levels 0.671
≤ 400 ng/mL 1.88 1.14–3.10
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free survival. Taketomi et al. [12] found that IBL > 1 L was
a significant predictor of extrahepatic recurrence following
hepatectomy. Sasaki et al. [13] demonstrated that IBL > 1 L
was a predictive factor of cancer-related death within
2 years after hepatectomy for HCC patients without micro-
vascular invasion. However, all of these studies focused on
the prognostic value of IBL after liver resection rather than
liver transplantation. Previous studies have identified that
IBL during LT has adverse effects on post-transplant out-
come [14–17]. However, the results from these studies
were mainly obtained from data of patients with benign
end-stage liver diseases, without considering HCC patients
independently, as well as the relationship between IBL and
tumor recurrence. Recently, a study from our center dem-
onstrated that IBL during LT was a significant prognostic
factor for long-term survival of HCC patients after LT [18].
Therefore, we further assessed the prognostic value of IBL
on HCC recurrence after LT. By using threshold analysis,
we found that when IBL was > 4 L, patients showed signifi-
cantly higher recurrence rates. In multivariate analysis,
IBL > 4 L was a significant prognostic factor for cumulative
recurrence rates and early recurrence. We also found that
tumor characteristics, including serum AFP levels, either
macro- or microvascular invasion, and the Milan criteria,
were significant independent predictors of HCC recurrence
after LT, which is consistent with previous reports [11, 19,
20]. Additionally, we found that patients aged younger than
60 years had higher recurrence rates, probably because of
more advanced and aggressive HCC in young people [21].
Previous studies have suggested that perioperative
blood transfusion is significantly associated with HCC
recurrence after LT [17, 22, 23]. However, we did not
find any adverse effects of packed red blood cell transfu-
sion on outcome in our study. In contrast, excessive IBL
was a significant predictor of outcome by univariate and
multivariate analyses. Because not all of these previous
studies included IBL in their analysis, we speculate that
the correlation between transfusion and poor onco-
logical outcome might be partly because of unmeasured
effects of IBL [3]. IBL is probably a more sensitive pre-
dictor of HCC recurrence than blood transfusion.
Because excessive IBL was an important prognostic fac-
tor of HCC recurrence after LT, the potential factors affect-
ing profuse hemorrhage need to be investigated. Although
blood loss during LT is multifactorial, the major causes of
excessive IBL are technical difficulties and pre-existing ab-
normalities of the hemostatic system [24]. Previous studies
have shown that the presence of ascites [25], preoperative
MELD score [26], and operation time [16] are risk factors
of IBL during LT. Similar to these studies, these factors
were determined as independent risk factors of excessive
IBL in our study. The presence of ascites and a high MELD
score preoperatively indicate more severe liver dysfunction.
Additionally, there might be a relationship between ascites
and fibrinolytic activity [27]; therefore, severe coagulopathy
could be aggravated by ascites.
Although we showed that excessive blood loss was an
independent predictor of HCC recurrence after LT, we
cannot conclude that excessive IBL directly leads to a
worse cancer outcome. There are several potential expla-
nations. Excessive IBL is a consequence of mixed factors
and reflects worse pre-transplant conditions combined
with technical difficulties. This condition also reflects
more manipulation of the liver at the time of hepatec-
tomy, which possibly leads to more tumor shedding at
that time [3]. However, profuse hemorrhage may result in
tissue hypoperfusion and hypoxia for a long time, which
in turn may lead to systemic inflammation and impaired
antitumor immunity [28]. Additionally, a hypoxic environ-
ment could promote epithelial-mesenchymal transition,
which makes the residual tumor cells more aggressive.
Because patients with vascular invasion are more likely
to harbor micrometastases, the effect of excessive IBL
should be greater in these patients. Our study verified
this hypothesis. By performing stratified analysis, we
found a significant interaction between excessive IBL
and vascular invasion. For patients with vascular inva-
sion, IBL > 4 L was an independent predictor of HCC
recurrence, in addition to elevated AFP levels and ex-
ceeding the Milan criteria.
Table 6 Predictors of recurrence after LT for HCC according to vascular invasion
Vascular invasion (n = 172) Non-vascular invasion (n = 307)
HR 95 % CI P value HR 95 % CI P value
Age <60 years 1.46 0.91–2.34 0.116 1.40 0.87-2.25 0.167
AFP levels > 400 ng/mL 1.53 1.04–2.24 0.031 1.99 1.31–3.02 0.001
Poor differentiation 1.09 0.68–1.73 0.729 1.37 0.63–2.98 0.423
Beyond Milan criteria 3.01 1.94–4.87 <0.001 1.38 0.90–2.10 0.139
IBL > 4 L 2.86 1.76–4.64 <0.001 1.57 0.87–2.85 0.138
Table 7 Multivariate analysis of risk factors for IBL > 4 L
Variable HR 95 % CI P value
History of variceal bleeding 1.51 0.75–3.07 0.253
History of abdominal surgery 1.68 0.89–3.15 0.108
Ascites 2.61 1.32–5.14 0.006
MELD score > 15 3.25 1.84–5.75 <0.001
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Several limitations of our study should be noted. First, as
a retrospective study, there was a potential for inclusion,
exclusion, and recall bias of patients and data. Second, con-
sidering that IBL was estimated by the anesthesiologist and
circuit nurse, the actual degree of IBL may have been
underestimated or overestimated. Assessment of IBL using
the concept of red cell mass, which was calculated based
on the perioperative change in hematocrit, might be more
precise [29]. However, this method is impractical because
assessment of hematocrit is not routinely conducted in our
center. Additionally, because of the small number of pa-
tients (n = 69, 14.4 %) in our single center, further multi-
center studies are required to confirm the relationship
between IBL and post-transplant tumor recurrence.
Conclusions
This study shows that excessive IBL, particularly IBL >
4 L, is an independent predictor of HCC recurrence after
LT. Excessive blood loss results in a significantly worse
outcome, especially in patients with vascular invasion.
These findings highlight the importance of minimizing
operative blood loss and imply that patients with excessive
blood loss should be monitored more closely after LT.
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